Lotus Pharmaceutical Co., Ltd. (1795) Reports Strong Q4 2025 Earnings with EPS of NT$18.14
NQ Score
65/100
N1 Content Completeness
4
AI Summary (NQ-processed)
Lotus Pharmaceutical Co., Ltd. (1795) announced its fourth quarter 2025 financial results, reporting a basic earnings per share (EPS) of NT$18.14. The company achieved quarterly revenue of NT$20.509 billion and a net profit after tax of NT$4.720 billion, solidifying its position as a leading company in Taiwan's biotechnology and healthcare sector.
AI analysis data is not yet available.
Frequently Asked Questions
- Q: What is Lotus Pharmaceutical's stock code?
- A: Lotus Pharmaceutical's stock code is 1795.
- Q: What were the key financial highlights for Lotus Pharmaceutical in Q4 2025?
- A: In Q4 2025, Lotus Pharmaceutical reported a basic EPS of NT$18.14, operating revenue of NT$20.509 billion, and a net profit after tax of NT$4.720 billion.
- Q: What industry does Lotus Pharmaceutical operate in?
- A: Lotus Pharmaceutical operates in the biotechnology and healthcare industry.